Investment Opportunities - The Haggerston BioHealth marketplace channel offers at least 4 exclusive stock tips weekly, focusing on Pharma, Biotech, and Healthcare sectors, alongside access to investment bank-grade financial models and research [1] - The group caters to both novice and experienced biotech investors, providing catalysts, buy/sell ratings, product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis for Big Pharma companies [2] Company Overview - Viatris (NASDAQ: VTRS) was formed in 2020 through the merger of generics drug giant Mylan and Pfizer's Upjohn business [2] - The company's Q3 2024 earnings announcement was preceded by a detailed overview, highlighting its strategic position in the generics and pharmaceutical markets [2] Analyst Background - Edmund Ingham, a biotech consultant with over 5 years of experience covering biotech, healthcare, and pharma, leads the Haggerston BioHealth investing group [2] - He has compiled detailed reports on over 1,000 companies, providing in-depth insights into the biotech and healthcare sectors [2]

Core Insights - The article emphasizes the importance of the Zacks Rank system and Style Scores in identifying strong stocks, particularly for value investors [1][3] - Viatris (VTRS) is highlighted as a strong value stock, currently holding a Zacks Rank of 2 (Buy) and a Value grade of A [3][6] Valuation Metrics - VTRS has a Price-to-Sales (P/S) ratio of 0.93, which is below the industry average of 1.3, indicating potential undervaluation [4] - The Price-to-Cash Flow (P/CF) ratio for VTRS is 7.42, significantly lower than the industry average of 19.92, suggesting a solid cash outlook [5] - Over the past year, VTRS's P/CF has fluctuated between 4.59 and 8.41, with a median of 6.15, further supporting its valuation as attractive [5] Earnings Outlook - The strength of VTRS's earnings outlook contributes to its classification as an impressive value stock at the moment [6]

Company Overview - Viatris Inc. is a strong global and diverse company with operations in 165 countries, generating $15 billion in revenue over the last 12 months [3][4] - The company reported an adjusted EBITDA of $4.8 billion and free cash flow of $2.4 billion, indicating significant financial strength [3] Product Portfolio - Viatris is home to several iconic pharmaceutical brands, including Lipitor, Lyrica, Celebrex, Norvasc, and Viagra, which are key components of its business strategy [3] Conference Presentation - The presentation at the J.P. Morgan Healthcare Conference included a brief introduction by CEO Scott Smith, followed by a Q&A session with the management team [1][2] - The company will not provide guidance for the full year 2024 or for 2025 during this presentation [2]

Key Points Company Overview 1. **Company Name and Stock Symbol**: Viatris Inc. (NASDAQ: VTRS) 2. **Event**: 43rd Annual J.P. Morgan Healthcare Conference 2025 3. **Date and Time**: January 14, 2025, 11:15 AM ET 4. **Participants**: - Scott Smith - CEO - Doretta Mistras - CFO - Philippe Martin - Chief R&D Officer - Corinne Le Goff - Chief Commercial Officer - Chris Schott - JPMorgan [1] Forward-Looking Statement 1. **No Guidance Provided**: The company will not be commenting on the full year 2024 or providing guidance for 2025 during the presentation. [2] Financial Highlights 1. **Revenue**: $15 billion in the last 12 months 2. **Adjusted EBITDA**: $4.8 billion in the last 12 months 3. **Free Cash Flow**: $2.4 billion in the last 12 months 4. **Financial Strength**: Viatris demonstrates tremendous financial strength [3] Business Segments 1. **Global Generics Business**: Strong global generics business 2. **Iconic Brands**: Home to iconic brands in the pharma world, including Lipitor, Lyrica, Celebrex, Norvasc, Viagra, etc. [3] Geographic Presence 1. **Global Operations**: Operates in 165 countries around the world [4]

43rd Annual J.P. Morgan Healthcare Conference Forward Looking Statements & Non-GAAP Financial Measures Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about our balanced capital allocation framework; expect capital allocation to be more heavily weighted towards capital return i ...

PITTSBURGH, Jan. 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025. The company's presentation and fireside chat will begin at 8:15 a.m. PT / 11:15 a.m. ET.A live webcast of the event can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the sam ...

Conservative Income Portfolio - The Conservative Income Portfolio targets the best value stocks with the highest margins of safety and uses the best-priced options to further lower investment volatility [1] - The Enhanced Equity Income Solutions Portfolio within the Conservative Income Portfolio is designed to reduce volatility while generating 7-9% yields [1] - The portfolio offers an 11-month money-back guarantee for first-time members [1] Viatris Inc (VTRS) - Viatris Inc (NASDAQ: VTRS) has been consistently rated as a "hold" since early 2021, with no "buy" or "sell" ratings issued during that period [2] Trapping Value and Preferred Stock Trader - Trapping Value is a team of analysts with over 40 years of combined experience in generating options income while focusing on capital preservation [3] - Trapping Value runs the Conservative Income Portfolio in partnership with Preferred Stock Trader, which features two income-generating portfolios and a bond ladder [3] - The Covered Calls Portfolio focuses on lower volatility income investing with an emphasis on capital preservation [2] - The Fixed Income Portfolio focuses on buying securities with high income potential and heavy undervaluation relative to comparatives [2]

Biomarker data from CARE study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the Annals of the Rheumatic DiseasesPITTSBURGH, Dec. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The results, published in Lancet Rheumatologyi, showed cenerimod 4 mg demonstrated clinically mea ...

Viatris Inc. (NASDAQ:VTRS) Jefferies London Healthcare Conference Transcript November 21, 2024 5:30 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Corinne Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo All right. Good morning, everybody. Thanks. Why don’t we get started? For those of you who don’t know me, I’m Glen Santangelo. I’m the analyst at Jefferi ...

Viatris Inc. (NASDAQ:VTRS) Jefferies London Healthcare Conference Transcript November 21, 2024 5:30 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Corinne Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo All right. Good morning, everybody. Thanks. Why don’t we get started? For those of you who don’t know me, I’m Glen Santangelo. I’m the analyst at Jefferi ...